NVCT — Nuvectis Pharma Cashflow Statement
0.000.00%
- $218.36m
- $199.83m
Annual cashflow statement for Nuvectis Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 0.01 | -12.9 | -19.1 | -22.3 | -19 |
Non-Cash Items | — | 1.89 | 1.71 | 4.71 | 4.86 |
Other Non-Cash Items | |||||
Changes in Working Capital | -0.01 | 1.49 | 3.82 | 1.6 | 1.9 |
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | 0 | -9.5 | -13.6 | -16 | -12.2 |
Other Investing Cash Flow Items | 0 | 0 | 0 | — | 0 |
Other Investing Cash Flow | |||||
Cash from Investing Activities | 0 | 0 | 0 | — | 0 |
Financing Cash Flow Items | 0 | — | -4.07 | -1.39 | -0.382 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 0 | 15.2 | 27.8 | 15.1 | 11.7 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0 | 5.74 | 14.3 | -0.867 | -0.593 |